CSE Bulletin: Fundamental Change - FogChain Corp./Avisa Diagnostics Inc.

Avisa Diagnostics Inc., the issuer resulting from a Fundamental Change of FogChain Corp. (FOG.X), has been approved for listing.

Listing and disclosure documents will be available at www.thecse.com on the trading date.

The Issuer offers an innovative approach to treating lung infections with rapid diagnostics to guide better clinical outcomes.

_________________________________

Avisa Diagnostics Inc., l'émetteur résultant d'un changement fondamental de FogChain Corp.(FOG.X), a été approuvé pour inscription.

Les documents de cotation et de divulgation seront disponibles sur www.thecse.com à la date de négociation.

L'émetteur propose une approche innovante pour traiter les infections pulmonaires avec des diagnostics rapides pour guider de meilleurs résultats cliniques.

Issuer/Émetteur: Avisa Diagnostics Inc.
Security Type/Titre: Common Shares/Actions ordinaires
Symbol(s)/Symbole(s): AVBT
Number of securities issued and outstanding/ Titres émis et en circulation: 41 219 310
Number of Securities reserved for issuance/ Titres réservés pour émission: 25 594 334
CSE Sector/Catégorie: Life Sciences/Sciences biologiques
CUSIP : 05380J 10 7
ISIN : CA 05380J 10 7 5
Old/Vieux CUSIP& ISIN: 34417N105/CA34417N1050
Boardlot/Quotité: 500
Consolidation: 1 New for 15 Old /1 nouveau pour 15 ancien
Trading Currency/Monnaie de négociation: CDN$/$CDN
Trading Date/Date de negociation: le 18 mai/May 2021
Other Exchanges/Autres marches: N/A
Fiscal Year end /Clôture de l'exercice financier: le 31 décembre/December
Transfer Agent/Agent des transferts: TSX Trust Company

 

The Exchange is accepting Market Maker applications for AVBT. Please email: Trading@theCSE.com

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com

Pour toute question, pour obtenir de l'information supplémentaire veuillez communiquer avec le service des inscriptions au 416 367-7340 ou par courriel à l'adresse: Listings@thecse.com

News Provided by Newsfile via QuoteMedia

The Conversation (0)

FogChain

FogChain Corp operates as a software as a service company. It provides a next-generation platform that seamlessly integrates application development and deployment that leverages a high-performance Fog based computing network to drive scale, and connects with the unique and ground-up built RadJav Blockchain. It operates in two segments namely Project development and Support and maintenance.

FogChain Corp operates as a software as a service company. It provides a next-generation platform that seamlessly integrates application development and deployment that leverages a high-performance Fog based computing network to drive scale, and connects with the unique and ground-up built RadJav Blockchain. It operates in two segments namely Project development and Support and maintenance. Keep Reading...
InMed Announces Results of 2025 Annual General and Special Meeting

InMed Announces Results of 2025 Annual General and Special Meeting

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general and special meeting of shareholders... Keep Reading...
InMed Provides Update on BayMedica Commercial Business

InMed Provides Update on BayMedica Commercial Business

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement.Recently, H.R. 5371, the "Continuing... Keep Reading...
Thian Chew, CEO of Invion

Invion Advances Global Strategy With New Licencing Agreement

Invion (ASX:IVX) has taken a major step forward with a new global licencing agreement that streamlines its rights across key cancer and infectious disease programs. The move gives the company a clearer path to advance its Photosoft technology, expand market opportunities and strengthen... Keep Reading...
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market is set to surpass a total value of US$1.75 trillion by the end of the decade, according to Evaluate Pharma.Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma... Keep Reading...
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

Data demonstrate a favorable bioavailability profile of INM-901 oral formulationData will support design and planning of first in human clinical trialsPreparing for pre-IND meeting with the FDA InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company... Keep Reading...

Interactive Chart

Latest Press Releases

Related News